CATEGORY 60 AUSTRALASIAN DENTIST Hyaluronidase, commonly referred to as Hyalase, is one of the most important agents in aesthetic medicine. While it is often described simply as a product used to “dissolve ller,” this terminology does not accurately re ect its biological behaviour, nor does it capture its critical role in emergency management. In contemporary practice, hyaluronidase should be understood not only as a tool for elective correction, but as an essential medication that underpins safe injectable practice. e concept of “dissolving ller” is increasingly being challenged. Hyaluronidase does not reliably or predictably eliminate hyaluronic acid (HA) ller in a complete or uniform way. Instead, it acts on a complex system in which ller is integrated into surrounding tissue. At a molecular level, hyaluronidase cleaves HA polymers into smaller fragments, reducing the viscosity, cohesivity, and hydrophilicity of the gel. e clinical e ect is often a softening of the treated area, a reduction in swelling, and an improvement in tissue pliability. However, imaging studies have demonstrated that residual HA frequently persists even after multiple treatment sessions, highlighting that the clinical improvement observed is better described as modi cation rather than complete removal. is distinction is important, particularly in the context of patient communication and consent. When hyaluronidase is used electively to address over lling, contour irregularities, or ller migration, its use is considered o -label. Patients must therefore be appropriately informed that the goal of treatment is improvement rather than guaranteed elimination, and that outcomes may vary depending on the type of ller, its duration in tissue, and the biological environment into which it has been placed. In addition, it is prudent to obtain consent for the potential use of hyaluronidase not only in planned corrective treatments, but also as part of complication management, should an adverse event arise. While elective use is important, the most critical role of hyaluronidase lies in the management of vascular occlusion. Vascular compromise remains one of the most serious complications associated with dermal ller injections. Although rare, its consequences can be severe, ranging from localised tissue ischaemia and necrosis to visual disturbance and, in the most devastating cases, irreversible blindness. e mechanisms underlying vascular occlusion are well described. Intravascular injection may result in the formation of an embolus that obstructs blood ow, while retrograde embolisation can allow ller to travel against the direction of arterial ow before moving into distal branches. e clinical presentation can vary widely depending on the vessel involved, but early signs such as blanching, pain, or livedo reticularis should always prompt immediate concern. When the ophthalmic circulation is a ected, symptoms may escalate rapidly to include visual disturbance, ptosis, or ophthalmoplegia. e de ning feature of vascular occlusion is its time-critical nature. e window for meaningful intervention is limited, particularly in cases involving the retinal circulation, where irreversible damage may occur within a very short timeframe. In this setting, hyaluronidase is not simply a treatment option; it is the standard of care. High-dose, repeated administration is required in an attempt to restore perfusion and minimise tissue damage. is reality necessitates a shift in how practitioners view hyaluronidase. It should not be regarded as an optional adjunct or a product used only in selected cases. Rather, it must be considered an essential emergency medication that is immediately available in any clinic performing dermal ller treatments. e absence of hyaluronidase in a clinical setting represents a signi cant limitation in the ability to respond to complications and may compromise patient safety. Equally important is the establishment of clear and structured protocols for its use. In the event of a complication, even experienced practitioners may experience a degree of stress or urgency that can impair decision-making. Without a prede ned plan, this can lead to delays in treatment or uncertainty in dosing and technique. Protocols should therefore be developed in advance, documented clearly, and readily accessible within the clinical environment. ese protocols should outline the recognition of vascular compromise, the preparation and dosing of hyaluronidase, and the steps required for escalation of care when necessary. However, the existence of a protocol alone is insu cient. Practitioners must be familiar with its application and con dent in its execution. is requires rehearsal and ongoing engagement with complication management strategies. Simulation of emergency scenarios, including the preparation and administration of hyaluronidase, can signi cantly improve response Rethinking Hyaluronidase: From Elective Tool to Emergency Essential CLINICAL Dr Giulia D’Anna By Dr Giulia D’Anna Founder, Dermal Distinction Academy Complications Expert – Aesthetic Medical Emergency Team (AMET)
RkJQdWJsaXNoZXIy MTc3NDk3Mw==